Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Oct 6;7(1):12783.
doi: 10.1038/s41598-017-13208-3.

Association between MGMT Promoter Methylation and Risk of Breast and Gynecologic Cancers: A Systematic Review and Meta-Analysis

Ru Chen  1 , Yonglan Zheng  2 , Lin Zhuo  3 , Shengfeng Wang  4
Affiliations
Meta-Analysis

Association between MGMT Promoter Methylation and Risk of Breast and Gynecologic Cancers: A Systematic Review and Meta-Analysis

Ru Chen et al. Sci Rep. .

Abstract

The role of the promoter methylation of O 6-methylguanine-DNA methyltransferase (MGMT) remains controversial for breast and gynecologic cancers. We conducted a meta-analysis to assess the association between hypermethylation of MGMT promoter and the risk of breast and gynecologic cancers. A comprehensive search was conducted in PubMed and Embase electronic databases up to 19th August 2017 for studies about the association between MGMT promoter hypermethylation and breast and gynecologic cancers. A total of 28 articles including 2,171 tumor tissues and 1,191 controls were involved in the meta-analysis. The pooled results showed that MGMT promoter methylation status was significantly associated with an increased risk of breast and gynecologic cancers (OR = 4.37, 95% CI: 2.68-7.13, P < 0.05). The associations were robust in subgroup analysis based on ethnicity, cancer type, methylation detection method, and control source. This meta-analysis indicated that MGMT hypermethylation was significantly associated with the risk of breast and gynecological cancers, and it may be utilized as a valuable biomarker in early diagnostics and prognostication of these cancers. Further efforts are needed to identify and validate this finding in prospective studies, especially in situation with new methylation testing methods and samples from plasma circulating DNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow diagram of the results of the search strategy.
Figure 2
Figure 2
Forest plot of MGMT promoter methylation and risk of breast and gynecological cancers in women.
Figure 3
Figure 3
Funnel plot to detect publication bias in the meta-analysis.
See this image and copyright information in PMC

References

    1. Ferlay, J. et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 10/24/2016 (2016).
    1. Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014;2:87. doi: 10.3389/fpubh.2014.00087. - DOI - PMC - PubMed
    1. Clarke-Pearson, D. & Soper, J. Gynecological cancer management: identification, diagnosis and treatment. (John Wiley & Sons, 2011).
    1. Laird PW. The power and the promise of DNA methylation markers. Nature Reviews Cancer. 2003;3:253–266. doi: 10.1038/nrc1045. - DOI - PubMed
    1. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nature Reviews Cancer. 2004;4:296–307. doi: 10.1038/nrc1319. - DOI - PubMed

Publication types

MeSH terms